Publications

Add filters (0)

34 results

Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development.

May 1, 2011

Biomarkers

Abstract The aim of this review is to discuss the potential usefulness of a novel class of biochemical markers, designated neoepitopes. Neoepitopes are post-translational modifications (PTMs) of proteins and are derived by processes, such as protease cleavage, citrullination, nitrosylation, glycosylation and isomerization. Each PTM results from a specific local physiological or pathobiological process. Identification of […]

Read publication

Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers.

January 1, 2010

Dis Markers

Abstract BACKGROUND Fibrosis is a central histological feature of chronic liver diseases and is characterized by the accumulation and reorganization of the extracellular matrix. The gold standard for assessment of fibrosis is histological evaluation of a percutaneous liver biopsy. Albeit a considerable effort have been invested in finding alternative non-invasive approaches, these have not been […]

Read publication

Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors.

October 15, 2004

J Cell Biochem

Abstract Biglycan is a small leucine-rich proteoglycan which is localized in the extracellular matrix of bone and other specialized connective tissues. Both biglycan mRNA and protein are up-regulated by transforming growth factor-beta(1) (TGF-beta(1)) and biglycan appears to influence TGF-beta(1) activity. In this study, we have investigated the mechanism by which TGF-beta(1), TGF-beta(2) and TGF-beta(3) stimulate […]

Read publication

Biglycan deficiency interferes with ovariectomy-induced bone loss.

December 1, 2003

J Bone Miner Res

Abstract UNLABELLED Biglycan is a matrix proteoglycan with a possible role in bone turnover. In a 4-week study with sham-operated or OVX biglycan-deficient or wildtype mice, we show that biglycan-deficient mice are resistant to OVX-induced trabecular bone loss and that there is a gender difference in the response to biglycan deficiency. INTRODUCTION Biglycan (bgn) is […]

Read publication